Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use | Zendy

Rebecca N Jerome | Zendy; Meghan M. Joly | Zendy; Nan Kennedy | Zendy; Jana K. Shirey-Rice | Zendy; Dan M. Roden | Zendy; Gordon R. Bernard | Zendy; Kenneth J. Holroyd | Zendy; Joshua C. Denny | Zendy; Jill M. Pulley | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use

Author(s) -

Rebecca N Jerome,

Meghan M. Joly,

Nan Kennedy,

Jana K. Shirey-Rice,

Dan M. Roden,

Gordon R. Bernard,

Kenneth J. Holroyd,

Joshua C. Denny,

Jill M. Pulley

Publication year - 2020

Publication title -

drug safety

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.377

H-Index - 124

eISSN - 1179-1942

pISSN - 0114-5916

DOI - 10.1007/s40264-020-00915-6

Subject(s) - medicine , computational biology , drug class , pharmacogenomics , drug , phenome , clinical trial , in silico , bioinformatics , drug development , gene , pharmacology , phenotype , genetics , biology

When a new drug or biologic product enters the market, its full spectrum of side effects is not yet fully understood, as use in the real world often uncovers nuances not suggested within the relatively narrow confines of preapproval preclinical and trial work.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research